Favipiravir Explained

Tradename:, Avifavir, Areplivir, others
Routes Of Administration:By mouth
Atc Prefix:J05
Atc Suffix:AX27
Legal Status:Rx-only
Cas Number:259793-96-9
Pubchem:492405
Drugbank:DB12466
Chemspiderid:431002
Unii:EW5GL2X7E0
Kegg:D09537
Chebi:134722
Chembl:221722
Synonyms:T-705, favipira, favilavir
Iupac Name:6-fluoro-3-hydroxypyrazine-2-carboxamide
C:5
H:4
F:1
N:3
O:2
Smiles:C1=C(N=C(C(=O)N1)C(=O)N)F
Stdinchi:1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
Stdinchikey:ZCGNOVWYSGBHAU-UHFFFAOYSA-N

Favipiravir, sold under the brand name Avigan among others,[1] is an antiviral medication used to treat influenza in Japan.[2] It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.[3]

It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co.[4] It became a generic drug in 2019.

Medical use

Favipiravir has been approved to treat influenza in Japan.[5] It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza.[5] [6] As of 2020, the probability of resistance developing appears low.[5]

Side effects

There is evidence that use during pregnancy may result in harm to the baby.[5] Teratogenic and embryotoxic effects were shown on four animal species.[5] [7] In one case report, a 6-month old infant developed benign bright blue discolouration of the cornea after treatment with favipiravir which resolved after treatment cessation.[8]

Mechanism of action

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.[9] Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations.[10] [11] In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.[12] However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment.[13]

Favipiravir-RTP is a nucleoside analogue. It mimics both guanosine and adenosine for the viral RdRP. Incorporating two such bases in a row stops primer extension, although it is unclear how as of 2013.[9]

Synthesis

There are multiple pathways to synthesize favipiravir.[14] [15] One synthesis starts with 3-Hydroxypicolinic acid[16], which is first reacted with thionyl chloride and then aqueous ammonia to produce 3-Hydroxypyrazine-2-carboxamide. The resulting material is nitrated with potassium nitrate and sulfuric acid to add a nitro group in the 6 position, which is then reduced using hydrazine hydrate to the corresponding amine. Finally, the amine is turned into a diazonium group using sodium nitrite and replaced with a fluorine group using hydrofluoric acid.

Society and culture

Legal status

The US Department of Defense developed favipiravir in partnership with MediVector, Inc. as a broad-spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials, where it demonstrated safety in humans and efficacy against the influenza virus.[17] favipiravir remains unapproved in the UK and the USA.[18] In 2014, Japan approved favipiravir for treating influenza strains unresponsive to current antivirals.[19] Toyama Chemical initially hoped that favipiravir would become a new influenza medication that could replace oseltamivir (brand name Tamiflu). However, animal experiments show the potential for teratogenic effects, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.[20]

Despite limited data on efficacy, as of March 2021 favipiravir is widely prescribed for outpatient treatment of mild to moderate COVID-19 in Egypt,[21] Hungary[22] and Serbia.[23] Patients are required to sign a consent form before obtaining the drug.

Brand names

Favipiravir is sold under the brand names, Avifavir,[24] Avipiravir,[25] Areplivir,[26] FabiFlu,[27] Favipira,[28] Reeqonus,[29] [30] and Qifenda.

Use in Russia

Coronavir is the brand name of favipiravir used in Russia, where it is approved for the treatment of COVID-19. It is produced and sold by R-Pharm.[31] [32] Coronavir was approved for use in Russia in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use.[33]

Research

COVID-19

Favipiravir, as an antiviral drug, has been authorized for treating COVID-19 in several countries including Japan, Russia, Serbia, Turkey, India, and Thailand, under emergency provisions.[34] [35] [36] [37] A rapid meta-review in September 2020 (analyzing four studies) noted that the drug led to clinical and radiological improvements; however, no reduction in mortality or differences in oxygen-support requirement were observed and more rigorous studies were sought.[38] [39] A Cochrane Systematic review published in Feb 2024, noted that there is actually no real benefit with Favipiravir in treating Covid-19 in terms of mortality benefits, or admission to mechanical ventillation, or hospitalisation, and it may not make any difference in adverse effects or serious adverse effects.[40]

, large-cohort clinical trials are underway.[41]

Ebola

Research in 2014, suggested that favipiravir may have efficacy against Ebola based on studies in mouse models; efficacy in humans was unaddressed.[42] [43] [44]

During the 2014 West Africa Ebola virus outbreak, a French nurse who contracted Ebola while volunteering for Médecins Sans Frontières (MSF) in Liberia reportedly recovered after receiving a course of favipiravir.[45] A clinical trial investigating the use of favipiravir against Ebola virus disease began in Guéckédou, Guinea, in December 2014.[46] Preliminary results presented in 2016 at the Conference on Retroviruses and Opportunistic Infections (CROI), later published, showed a decrease in mortality in patients with low-to-moderate levels of virus in blood, but no effect on patients with high levels (the group at a higher risk of death).[47] [48] [49] The trial design was concomitantly criticised for using only historical controls.[50]

Nipah

Nipah virus is a causative agent of outbreaks of encephalitis with pneumonia and has a high case fatality rate. The first outbreak occurred in Malaysia-Singapore, related to contact with pigs in slaughterhouses and an outbreak in Philippines related to slaughter of horses, most other outbreaks have affected India and Bangladesh. in Bangladesh outbreaks are often associated with consumption of raw date palm sap contaminated by saliva and urine of fruit bats.[51] In a study published in the Scientific Reports, Syrian hamster model for Nipah virus infection was used, which closely mirrors most aspects of human disease, such as widespread vasculitis, pneumonia, and encephalitis. The hamsters were infected with a lethal dose of 104 PFU NiV-M via the intraperitoneal (i.p.) route similar to previous studies and treatment was initiated immediately after infection. Favipiravir was administered twice daily via the peroral (p.o.) route for 14 days. The treated hamsters displayed 100% survival and no obvious morbidity after lethal NiV challenge, whereas all the control cases died of severe disease.[52]

Other

In experiments in animals favipiravir has shown activity against West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.[53] Activity against enteroviruses[54] and Rift Valley fever virus has also been demonstrated.[55] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.[56] The agent has also shown some efficacy against rabies,[57] and has been used experimentally in some humans infected with the virus.[58]

Tautomerism

The possible tautomerism of favipiravir has been investigated computationally[59] and experimentally.[60] It was found that the enol-like form was substantially more stable in organic solvents than the keto-like form, meaning that Favipiravir likely exists almost exclusively in the enol-like form. In aqueous solution the keto-like tautomer is substantially stabilized due to the specific interaction with the water molecules. Upon protonation the keto form is switched on.

External links

Notes and References

  1. News: Glenmark launches Covid-19 drug FabiFlu, priced at Rs 103 per tablet. Business Standard India. 20 June 2020. Press Trust of India.
  2. Du YX, Chen XP . Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection . Clinical Pharmacology and Therapeutics . 108 . 2 . 242–247 . August 2020 . 32246834 . 10.1002/cpt.1844 . free .
  3. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD . T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections . Antiviral Research . 82 . 3 . 95–102 . June 2009 . 19428599 . 7127082 . 10.1016/j.antiviral.2009.02.198 .
  4. News: Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals. Fierce Pharma . 20 April 2020. 22 June 2016. EJ Lane.
  5. Shiraki K, Daikoku T . Favipiravir, an anti-influenza drug against life-threatening RNA virus infections . Pharmacology & Therapeutics . 209 . 107512 . May 2020 . 32097670 . 7102570 . 10.1016/j.pharmthera.2020.107512 .
  6. Web site: Information of Avigan Tablet in relation to Covid-19 . FUJIFILM Toyama Chemical Co., Ltd .
  7. Pilkington V, Pepperrell T, Hill A . A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? . Journal of Virus Eradication . 6 . 2 . 45–51 . April 2020 . 32405421 . 7331506 . 10.1016/S2055-6640(20)30016-9 .
  8. Jiravisitkul P, Thonginnetra S, Wongvisavavit R . Case report: Favipiravir-induced bluish corneal discoloration in infant with COVID-19 . Frontiers in Pediatrics . 11 . 1154814 . 2023 . 37152312 . 10154467 . 10.3389/fped.2023.1154814 . free .
  9. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J . The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase . PLOS ONE . 8 . 7 . e68347 . 2013 . 23874596 . 3707847 . 10.1371/journal.pone.0068347 . free . 2013PLoSO...868347J .
  10. Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X . Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques . PLOS Medicine . 15 . 3 . e1002535 . March 2018 . 29584730 . 5870946 . 10.1371/journal.pmed.1002535 . free .
  11. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y . Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells . The Journal of Antimicrobial Chemotherapy . 64 . 4 . 741–746 . October 2009 . 19643775 . 2740635 . 10.1093/jac/dkp274 .
  12. News: Ebola Drug From Japan May Emerge Among Key Candidates . 7 August 2014 . Bloomberg.com . Koons C .
  13. Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK . Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses . Antimicrobial Agents and Chemotherapy . 62 . 8 . e00766–18 . August 2018 . 29891600 . 6105843 . 10.1128/AAC.00766-18 .
  14. Furuta Y, Takahashi K.: Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both, WO 00/10569[P]. 2001-04-07.
  15. Guo, Qi; Xu, Mingshuo; Guo, Shuang; Zhu, Fuqiang; Xie, Yuanchao; Shen, Jingshan: The complete synthesis of favipiravir from 2-aminopyrazine in Chemical Papers 73 (2019) 1043–1051, .
  16. Fangyuan Shi; Zongtao Li; Lingjin Kong; Yuanchao Xie; Tao Zhang; Wenfang Xu: Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide in Drug Discoveries & Therapeutics 8 (2014) 117–120, .
  17. Web site: MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza . BioSpace . 5 May 2020.
  18. Lumby CK, Zhao L, Oporto M, Best T, Tutill H, Shah D, Veys P, Williams R, Worth A, Illingworth CJ, Breuer J . Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child . Clinical Infectious Diseases . 71 . 7 . e191–e194 . October 2020 . 32124919 . 10.1093/cid/ciaa023 . free .
  19. Hayden FG, Shindo N . Influenza virus polymerase inhibitors in clinical development . Current Opinion in Infectious Diseases . 32 . 2 . 176–186 . April 2019 . 30724789 . 6416007 . 10.1097/QCO.0000000000000532 . free .
  20. Web site: https://diamond.jp/articles/-/49229 . ja:条件付き承認で普及に足かせ 富山化学インフル薬の"無念" . Conditional approval hinders popularization Toyama chemical flu drug's "disappointment" . 25 February 2014 . ja. 25 February 2014 .
  21. News: 11 March 2021. تعرف على علاج كورونا المطروح بالصيدليات المصرية وسعره ومدى نجاعته . Learn about the Corona treatment offered in Egyptian pharmacies, its price, and its efficacy . . live. 21 January 2022. https://web.archive.org/web/20211223010942/https://www.aljazeera.net/news/healthmedicine/2021/3/11/%d8%aa%d8%b9%d8%b1%d9%81-%d8%b9%d9%84%d9%89-%d8%b9%d9%84%d8%a7%d8%ac-%d9%83%d9%88%d8%b1%d9%88%d9%86%d8%a7-%d8%a7%d9%84%d9%85%d8%b7%d8%b1%d9%88%d8%ad. 23 December 2021.
  22. Web site: 11 March 2021. A kórházakat tehermentesítheti az egyforintos koronavírus-gyógyszer . Hospitals can be relieved of the one-forint coronavirus medicine . 30 March 2021. telex. hu.
  23. Web site: 22 November 2021. Korona virus: Koji se lekovi protiv Kovida-19 koriste u Srbiji . Corona virus: What anti-Covid-19 drugs are used in Serbia.
  24. Web site: Avifavir . Medum.ru . Russian drug reference .
  25. Web site: EVA Pharma Announces Availability of Antiviral Avipiravir® Tablets in Egyptian Pharmacies. live. https://web.archive.org/web/20220121091953/https://web.evapharma.com/eva-pharma-announces-availability-of-antiviral-avipiravir-tablets-in-egyptian-pharmacies/. 21 January 2022. EVA Pharma. 21 January 2022.
  26. Web site: Arelpivir . Medum.ru . Russian drug reference .
  27. Web site: 'FabiFlu is the most economical COVID-19 treatment option': Glenmark's reply to Centre on alleged 'overpricing' . DNA India . 21 July 2020 . 22 July 2020.
  28. Web site: Favipira - Tablet - 200 mg - Beacon Pharmaceuticals Ltd. - Indications, Pharmacology, Dosage, Side Effects & other Generic Info . Medex . 22 July 2020.
  29. Web site: Broad-Spectrum Oral Antiviral Sales Surge for COVID-19 Treatment. 6 November 2021. www.precisionvaccinations.com.
  30. Web site: Favipiravir . 6 November 2021 . Appili Therapeutics . 6 November 2021 . https://web.archive.org/web/20211106002911/https://www.appilitherapeutics.com/favipiravir . dead .
  31. Web site: Russian firm gets approval for drug said to block coronavirus replication. July 8, 2020. in.reuters.com. 11 June 2023. 5 December 2023. https://web.archive.org/web/20231205104631/https://www.reuters.com/?edition-redirect=in. dead.
  32. Web site: Russia approves R-Pharm's Coronavir for Covid-19 treatment . Pharmaceutical Technology . 21 July 2020 . 9 July 2020.
  33. News: ((Reuters Staff)) . 2020-09-18. Russia approves first COVID-19 prescription drug for sale in pharmacies. fr. Reuters. 2020-09-20.
  34. Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M . Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir . Clinical Pharmacology and Therapeutics . 111 . 3 . 545–547 . March 2022 . 33882157 . 8251038 . 10.1002/cpt.2251 . free .
  35. News: 18 September 2020. Russia approves first COVID-19 prescription drug for sale in pharmacies. Reuters. 20 May 2021.
  36. Web site: Pulla P . 25 November 2020. Is Favipiravir Good for COVID-19? Clinical Trial Says No, Press Release Says Yes. 20 May 2021. The Wire Science.
  37. News: Wipatayotin A . 8 August 2021. More patients to be given Favipiravir. 29 November 2021. The Bangkok Post.
  38. Vaidyanathan G . Scientists criticize use of unproven COVID drugs in India . Nature . 587 . 7833 . 187–188 . November 2020 . 33169025 . 10.1038/d41586-020-03105-7 . 2020Natur.587..187V . 226295778 .
  39. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P . Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis . Virology Journal . 17 . 1 . 141 . September 2020 . 32972430 . 7512218 . 10.1186/s12985-020-01412-z . free .
  40. Korula P, Alexander H, John JS, Kirubakaran R, Singh B, Tharyan P, Rupali P . Favipiravir for treating COVID-19 . The Cochrane Database of Systematic Reviews . 2 . 2 . CD015219 . February 2024 . 38314855 . 10840071 . 10.1002/14651858.CD015219.pub2 . Cochrane Infectious Diseases Group .
  41. News: Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial . PRINCIPLE Trial . 8 April 2021 . Led by University of Oxford researchers, PRINCIPLE is one of the UK Government's national priority platform trials for COVID-19 treatments and was set-up with the intention that drugs shown to have a clinical benefit could be rapidly introduced into routine NHS care..
  42. Gatherer D . The 2014 Ebola virus disease outbreak in West Africa . The Journal of General Virology . 95 . Pt 8 . 1619–1624 . August 2014 . 24795448 . 10.1099/vir.0.067199-0 . free .
  43. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S . Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model . Antiviral Research . 105 . 17–21 . May 2014 . 24583123 . 10.1016/j.antiviral.2014.02.014 . free .
  44. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS . Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model . Antiviral Research . 104 . 153–155 . April 2014 . 24462697 . 10.1016/j.antiviral.2014.01.012 .
  45. News: First French Ebola patient leaves hospital. Reuters. 4 October 2016.
  46. Web site: Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea. AllAfrica – All the Time. 28 December 2014.
  47. Web site: Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea. CROIconference.org. 24 February 2015 . 17 March 2016.
  48. Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Kighoma PM, Koundouno FR, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D . Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea . PLOS Medicine . 13 . 3 . e1001967 . March 2016 . 26930627 . 4773183 . 10.1371/journal.pmed.1001967 . free .
  49. News: Ebola Drug Aids Some in a Study in West Africa . . Fink S . 4 February 2015.
  50. Results from encouraging Ebola trial scrutinized . Cohen J . . 26 February 2015 . 21 January 2016 . 10.1126/science.aaa7912.
  51. Banerjee S, Gupta N, Kodan P, Mittal A, Ray Y, Nischal N, Soneja M, Biswas A, Wig N . Nipah virus disease: A rare and intractable disease . Intractable & Rare Diseases Research . 8 . 1 . 1–8 . February 2019 . 30881850 . 6409114 . 10.5582/irdr.2018.01130 .
  52. Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN . Favipiravir (T-705) protects against Nipah virus infection in the hamster model . Scientific Reports . 8 . 1 . 7604 . May 2018 . 29765101 . 5954062 . 10.1038/s41598-018-25780-3 . 2018NatSR...8.7604D .
  53. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD . T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections . Antiviral Research . 82 . 3 . 95–102 . June 2009 . 19428599 . 7127082 . 10.1016/j.antiviral.2009.02.198 .
  54. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL . Favipiravir (T-705), a novel viral RNA polymerase inhibitor . Antiviral Research . 100 . 2 . 446–454 . November 2013 . 24084488 . 3880838 . 10.1016/j.antiviral.2013.09.015 .
  55. Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL . Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever . PLOS Neglected Tropical Diseases . 8 . 4 . e2790 . April 2014 . 24722586 . 3983105 . 10.1371/journal.pntd.0002790 . free .
  56. Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP . Zika Virus: Where Is the Treatment? . Current Treatment Options in Infectious Diseases . 8 . 3 . 208–211 . 2016 . 27547128 . 4969322 . 10.1007/s40506-016-0083-7 .
  57. Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A . Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis . The Journal of Infectious Diseases . 213 . 8 . 1253–1261 . April 2016 . 26655300 . 4799667 . 10.1093/infdis/jiv586 .
  58. Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM . Human Rabies - Virginia, 2017 . en-us . MMWR. Morbidity and Mortality Weekly Report . 67 . 5152 . 1410–1414 . January 2019 . 30605446 . 6334827 . 10.15585/mmwr.mm675152a2 .
  59. Antonov L . Favipiravir tautomerism: a theoretical insight . Theoretical Chemistry Accounts . 139 . 8 . 145 . 2020 . 32834770 . 7415411 . 10.1007/s00214-020-02656-2 . free .
  60. Deneva V, Slavova S, Kumanova A, Vassilev N, Nedeltcheva-Antonova D, Antonov L . Favipiravir-Tautomeric and Complexation Properties in Solution . Pharmaceuticals . 16 . 1 . 45 . December 2022 . 36678542 . 9864296 . 10.3390/ph16010045 . free .